Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Tilray Brands Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 53.7× Tilray Brands Inc's market cap, and iShares iBoxx $ Inv Grade Corporate Bond ETF is more actively traded (37,320,110 versus 9,099,075). Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Tilray Brands Inc for 31 Days on average.
| LQD | TLRY | |
|---|---|---|
Market Cap | $28.50B | $530.54M |
Volume | 37,320,110 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $21.00 |
52-Week Low | $101.83 | $3.57 |
Typical Hold Time | 125 Days | 31 Days |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.41 with a slight 0.28% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs. The fund maintains consistent dividend distributions with recent payouts around $0.44-0.46 per share.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking exposure to investment-grade corporate bonds, though near-term price pressure may persist until bond market conditions stabilize.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
